BelleTorus Corporation
BelleTorus Corporation, known as Belle.ai, is dedicated to enhancing global skin healthcare access through innovative AI technology. Their mission is to assist healthcare professionals in addressing the unmet demands for dermatology by providing tools that analyze over 1,600 skin conditions from smartphone images. Belle.ai's technology supports healthcare providers with objective scoring for immune-mediated skin disorders and is utilized by researchers and pharmaceutical companies worldwide to study and evaluate skin health treatments.
BelleTorus Corporation
245 First Street Riverview II, 18th Floor Cambridge, MA 02142 USA
What We Do
Uses geometric analyses from smartphone clinical images to find similar reference images and text for over 1,600 skin conditions, including rare and neglected tropical skin conditions.
AI software that compares dermoscopy images of pigmented lesions against a repository to identify similar geometric patterns, assisting healthcare professionals in patient assessment.
Proposes calculation for routine IGA severity numbers for acne-related conditions based on comparison to reference images and text.
Proposes objective initial assessment of routine Psoriasis Area Severity Index scoring for patients independently diagnosed with psoriasis.
Proposes objective initial assessment of routine Eczema Area Severity Index scoring for patients independently diagnosed with eczema.
Proposes objective initial assessment of routine Nail Area Psoriasis Severity Index scoring for patients independently diagnosed with nail psoriasis.
Digital Health Technologies
News & Updates
Belle.ai was chosen by CMS to showcase its AI technology for dermatology at the inaugural AI Demo Day.
Belle.ai, in collaboration with UHP, received a contract from ARPA-H to enhance pediatric healthcare using AI.
ARPA-H awarded Belle.ai a $3.5 million contract to expand pediatric telehealth services through AI technology.